Drugs / MV-s-NAP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04521764 | Sep 2020 → Aug 2027 expected | breast adenocarcinoma, female breast carcinoma, invasive breast carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-s-NAP | “We engineered an MV strain to express the secretory form of NAP (MV-s-NAP)” PMID 36092362 ↗ Jul 2022 |
| Route | Other | “intratumoral administration” NCT04521764 ↗ |